Investing.com - Cardiff Oncology (NASDAQ: CRDF) reported second quarter EPS of $-0.260, $0.01 worse than the analyst estimate of $-0.250. Revenue for the quarter came in at $163K versus the consensus estimate of $58.75K.
Cardiff Oncology's stock price closed at $2.13. It is down -37.170% in the last 3 months and up 11.520% in the last 12 months.
Cardiff Oncology saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Cardiff Oncology's stock price’s past reactions to earnings here.
According to InvestingPro, Cardiff Oncology's Financial Health score is "fair performance".
Check out Cardiff Oncology's recent earnings performance, and Cardiff Oncology's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar